Cargando…

Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort

BACKGROUND: Most HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly active antiretroviral therapy (HAART). However, a subset of individuals exhibit very poor CD4 T-cell recovery despite effective control of HIV-RNA viraemia. We evaluated CD4 T-cell proli...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakanjako, Damalie, Ssewanyana, Isaac, Nabatanzi, Rose, Kiragga, Agnes, Kamya, Moses R, Cao, Huyen, Mayanja-Kizza, Harriet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706234/
https://www.ncbi.nlm.nih.gov/pubmed/23786370
http://dx.doi.org/10.1186/1471-2172-14-26
_version_ 1782476521659695104
author Nakanjako, Damalie
Ssewanyana, Isaac
Nabatanzi, Rose
Kiragga, Agnes
Kamya, Moses R
Cao, Huyen
Mayanja-Kizza, Harriet
author_facet Nakanjako, Damalie
Ssewanyana, Isaac
Nabatanzi, Rose
Kiragga, Agnes
Kamya, Moses R
Cao, Huyen
Mayanja-Kizza, Harriet
author_sort Nakanjako, Damalie
collection PubMed
description BACKGROUND: Most HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly active antiretroviral therapy (HAART). However, a subset of individuals exhibit very poor CD4 T-cell recovery despite effective control of HIV-RNA viraemia. We evaluated CD4 T-cell proliferation among suboptimal responders and its correlation with CD4 T-cell activation. METHODS: The magnitude of CD4 increase (difference between absolute CD4 counts at baseline and absolute CD4 counts at 4 years of ART) was grouped into 4 quartiles for the 211 patients with sustained HIV-RNA viral suppression. Cases of ‘Suboptimal immune responders’ included patients within the lowest quartile [Median CD4 increase 165 (Range −43-298) cells/μl; n=52] and a comparison group of ‘Optimal immune responders’ was defined as patients within the highest quartile of CD4 increase [Median CD4 increase 528 (Range 417–878) cells/μl; n=52]. Frozen PBMC were thawed and analysed from a convenient sample of 39 suboptimal responders and 48 optimal responders after 4 years of suppressive antiretroviral therapy. T-cell activation was measured by proportions of T-cells expressing surface marker CD38 and HLADR (CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ cells). T-cell proliferation was determined by the extent of carboxyfluorescein diacetate succinimidyl ester (CFSE) dye dilution on culture day 5 of PBMCs in the presence of antigen (SEB, PPD, CMVpp65, GagA and GagD). Samples were analyzed on a FACS Calibur flow cytometer and flow data was analyzed using FlowJo and GraphPad. RESULTS: Overall, CD4 T-cell proliferation on stimulation with SEB, PPD, CMVpp65, Gag A and Gag D.antigens, was lower among suboptimal than optimal responders; this was significant for SEB (CD4+ p=0.003; CD8+ p=0.048) and PPD antigens (CD8+ p=0.038). Among suboptimal responders, T-cell proliferation decreased with increasing immune activation (Negative correlation; slope = −0.13±−0.11) but not among optimal responders. CONCLUSION: T-cell immune activation and exhaustion were associated with poor proliferation among suboptimal responders to HAART despite sustained viral suppression. We recommend studies to further understand the mechanisms leading to impaired T-cell function among suboptimal responders as well as the potential role of immune modulation in optimizing CD4 count and functional recovery after HAART.
format Online
Article
Text
id pubmed-3706234
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37062342013-07-10 Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort Nakanjako, Damalie Ssewanyana, Isaac Nabatanzi, Rose Kiragga, Agnes Kamya, Moses R Cao, Huyen Mayanja-Kizza, Harriet BMC Immunol Research Article BACKGROUND: Most HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly active antiretroviral therapy (HAART). However, a subset of individuals exhibit very poor CD4 T-cell recovery despite effective control of HIV-RNA viraemia. We evaluated CD4 T-cell proliferation among suboptimal responders and its correlation with CD4 T-cell activation. METHODS: The magnitude of CD4 increase (difference between absolute CD4 counts at baseline and absolute CD4 counts at 4 years of ART) was grouped into 4 quartiles for the 211 patients with sustained HIV-RNA viral suppression. Cases of ‘Suboptimal immune responders’ included patients within the lowest quartile [Median CD4 increase 165 (Range −43-298) cells/μl; n=52] and a comparison group of ‘Optimal immune responders’ was defined as patients within the highest quartile of CD4 increase [Median CD4 increase 528 (Range 417–878) cells/μl; n=52]. Frozen PBMC were thawed and analysed from a convenient sample of 39 suboptimal responders and 48 optimal responders after 4 years of suppressive antiretroviral therapy. T-cell activation was measured by proportions of T-cells expressing surface marker CD38 and HLADR (CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ cells). T-cell proliferation was determined by the extent of carboxyfluorescein diacetate succinimidyl ester (CFSE) dye dilution on culture day 5 of PBMCs in the presence of antigen (SEB, PPD, CMVpp65, GagA and GagD). Samples were analyzed on a FACS Calibur flow cytometer and flow data was analyzed using FlowJo and GraphPad. RESULTS: Overall, CD4 T-cell proliferation on stimulation with SEB, PPD, CMVpp65, Gag A and Gag D.antigens, was lower among suboptimal than optimal responders; this was significant for SEB (CD4+ p=0.003; CD8+ p=0.048) and PPD antigens (CD8+ p=0.038). Among suboptimal responders, T-cell proliferation decreased with increasing immune activation (Negative correlation; slope = −0.13±−0.11) but not among optimal responders. CONCLUSION: T-cell immune activation and exhaustion were associated with poor proliferation among suboptimal responders to HAART despite sustained viral suppression. We recommend studies to further understand the mechanisms leading to impaired T-cell function among suboptimal responders as well as the potential role of immune modulation in optimizing CD4 count and functional recovery after HAART. BioMed Central 2013-06-20 /pmc/articles/PMC3706234/ /pubmed/23786370 http://dx.doi.org/10.1186/1471-2172-14-26 Text en Copyright © 2013 Nakanjako et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Nakanjako, Damalie
Ssewanyana, Isaac
Nabatanzi, Rose
Kiragga, Agnes
Kamya, Moses R
Cao, Huyen
Mayanja-Kizza, Harriet
Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort
title Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort
title_full Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort
title_fullStr Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort
title_full_unstemmed Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort
title_short Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort
title_sort impaired t-cell proliferation among haart-treated adults with suboptimal cd4 recovery in an african cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706234/
https://www.ncbi.nlm.nih.gov/pubmed/23786370
http://dx.doi.org/10.1186/1471-2172-14-26
work_keys_str_mv AT nakanjakodamalie impairedtcellproliferationamonghaarttreatedadultswithsuboptimalcd4recoveryinanafricancohort
AT ssewanyanaisaac impairedtcellproliferationamonghaarttreatedadultswithsuboptimalcd4recoveryinanafricancohort
AT nabatanzirose impairedtcellproliferationamonghaarttreatedadultswithsuboptimalcd4recoveryinanafricancohort
AT kiraggaagnes impairedtcellproliferationamonghaarttreatedadultswithsuboptimalcd4recoveryinanafricancohort
AT kamyamosesr impairedtcellproliferationamonghaarttreatedadultswithsuboptimalcd4recoveryinanafricancohort
AT caohuyen impairedtcellproliferationamonghaarttreatedadultswithsuboptimalcd4recoveryinanafricancohort
AT mayanjakizzaharriet impairedtcellproliferationamonghaarttreatedadultswithsuboptimalcd4recoveryinanafricancohort